Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
https://www.spglobal.com/spdji/en//documents/indexnews/announcements/20260904-1484999/1484999_shuffle5461-sept2026.pdf
Stocks · News reference
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics announced the grant of 57,000 restricted stock units (RSUs) to 11 newly hired employees as a material inducement for employment. The RSUs will vest over four years with 25% vesting annually, subject to continued employment. The company also announced that management will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026.
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, announced it will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. Management will participate in a fireside chat on Wednesday, September 16 at 1:50 p.m. ET. The company focuses on developing targeted topicals for chronic inflammatory skin diseases.
Arcutis Biotherapeutics shares are trading lower. The company announced its subsidiary Arcutis Canada secured Health Canada approval for roflumilast cream in pediatric atopic dermatitis patients.